# Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects

> **NCT06084663** · PHASE3 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis and Psoriatic Arthritis

## Interventions

- **DRUG:** Apremilast 30 mg Tablets
- **DRUG:** Otezla 30 mg film-coated tablets

## Key facts

- **NCT ID:** NCT06084663
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-15
- **Primary completion:** 2023-02-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084663, "Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06084663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*